Fighting Cancer: Allostery and Targeting Cancer Cell Metabolism

 March 23, 2016

The development of cancer is driven by the acquisition of multiple alterations in normal human cells that allow dysregulated proliferation. Join Stefan Gross of Agios Pharmaceuticals and Scott Edmondson of AstraZeneca as they discuss how targeting these unique adaptations could lead to drugs with potential to transform clinical outcomes across many cancer types.

Register Now!

What You Will Learn

• Rationale for Targeting Cancer Cell Metabolism
• Drugging Glycolysis: Activators of Pyruvate Kinase
• Targeting the TCA Cycle: Inhibitors of Isocitrate Dehydrogenase and Glutaminase

• Date: Thursday, March 23, 2017 @ 1 - 2pm CT
• Fee: Free to Attend
• Download Slides: Available Day of Broadcast